- Home
- INCY vs AKAM Comparison
INCY vs AKAM Comparison
Compare INCY & AKAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- AKAM
- Stock Information
- Founded
- INCY 1991
- AKAM 1998
- Country
- INCY United States
- AKAM United States
- Employees
- INCY N/A
- AKAM N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- AKAM Business Services
- Sector
- INCY Health Care
- AKAM Consumer Discretionary
- Exchange
- INCY Nasdaq
- AKAM Nasdaq
- Market Cap
- INCY 13.4B
- AKAM 12.2B
- IPO Year
- INCY 1993
- AKAM 1999
- Fundamental
- Price
- INCY $65.06
- AKAM $75.93
- Analyst Decision
- INCY Hold
- AKAM Buy
- Analyst Count
- INCY 19
- AKAM 21
- Target Price
- INCY $72.67
- AKAM $107.37
- AVG Volume (30 Days)
- INCY 1.8M
- AKAM 3.3M
- Earning Date
- INCY 04-29-2025
- AKAM 05-08-2025
- Dividend Yield
- INCY N/A
- AKAM N/A
- EPS Growth
- INCY N/A
- AKAM N/A
- EPS
- INCY 0.10
- AKAM 2.97
- Revenue
- INCY $4,413,226,000.00
- AKAM $4,019,337,000.00
- Revenue This Year
- INCY $13.29
- AKAM $5.61
- Revenue Next Year
- INCY $10.43
- AKAM $5.17
- P/E Ratio
- INCY $592.09
- AKAM $25.56
- Revenue Growth
- INCY 17.13
- AKAM 3.51
- 52 Week Low
- INCY $53.56
- AKAM $67.51
- 52 Week High
- INCY $83.95
- AKAM $106.80
- Technical
- Relative Strength Index (RSI)
- INCY 60.01
- AKAM 44.06
- Support Level
- INCY $63.51
- AKAM $75.75
- Resistance Level
- INCY $66.26
- AKAM $78.04
- Average True Range (ATR)
- INCY 1.60
- AKAM 1.72
- MACD
- INCY 0.32
- AKAM -0.27
- Stochastic Oscillator
- INCY 83.12
- AKAM 23.84
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About AKAM Akamai Technologies Inc.
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.